BerGenBio

Regulatory Filings • May 19, 2017

Abstract showing activity in MDS of BerGenBio's first-in-class AXL inhibitor, BGB324, accepted for presentation at ASCO Annual Meeting 2017

Abstract showing activity in MDS of BerGenBio's first-in-class AXL inhibitor, BGB324, accepted for presentation at ASCO Annual Meeting 2017

Bergen, Norway, May, 19 2017 - Leading oncology biopharmaceutical company

BerGenBio ASA, announces that its first-in-class small molecule Axl inhibitor

BGB324 will be featured in a poster presentation at the upcoming 2017 American

Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL from June 2-6,

2017. The presentation will focus on pre-clinical as well as clinical activity

of BGB324 in high-risk Myeloid Dysplastic Syndrome (MDS).

The details of the poster presentation are as follows:

Blockade of Axl with the small molecule inhibitor BGB324 shows activity in vitro

and in patients with high-risk MDS.

?       Poster Session: Hematologic Malignancies-Leukemia, Myelodysplastic

Syndromes, and Allotransplant

?       Abstract number: 7059

?       Monday Jun 5, 2017 8:00 AM - 11:30 AM (CT)

Further details can be found at http://abstracts.asco.org/.

About MDS

MDS refers to a range of conditions that can occur when the blood-forming cells

in the bone marrow are damaged, interfering with the making of new blood cells.

In about one-third of patients, MDS can progress into AML. Treatment typically

consists of supportive therapy and may include bone marrow stimulation,

hypomethylating agents and cytotoxic chemotherapy. Existing therapies are

particularly inadequate in patients with high risk MDS, who have a median

survival of five months.

About ASCO

From June 2 to June 6 2017, over 30,000 oncology professionals from around the

globe will meet in Chicago, IL, to discuss the latest advances in cancer therapy

during the 2017 ASCO Annual Meeting, organised by the American Society Of

Clinical Oncology (ASCO).

About BerGenBio ASA

BerGenBio (Bergen, Norway) is a clinical-stage biopharmaceutical company focused

on developing a pipeline of first-in-class Axl kinase inhibitors to treat

multiple cancer indications. The Company is a world leader in understanding the

central role of Axl kinase in promoting cancer spread, immune evasion and drug

resistance in multiple aggressive haematological and solid cancers.

BerGenBio's lead product, BGB324, is a selective, potent and orally bio

-available small molecule Axl inhibitor in Phase II clinical development in

three major cancer indications. It is the only selective Axl inhibitor in

clinical development. BGB324 is being developed by BerGenBio as a single agent

therapy in acute myeloid leukaemia (AML)/myeloid dysplastic syndrome (MDS) and

in combination with TARCEVA® (erlotinib) in advanced non-small-cell lung cancer

(NSCLC); and in combination with KEYTRUDA® (pembrolizumab) in advanced NSCLC and

triple negative breast cancer (TNBC) in collaboration with Merck & Co. Inc.

(MSD).

The Company is also developing a diversified pre-clinical pipeline of selective

Axl inhibitors including BGB149, anti-Axl monoclonal antibody.

For further information, please visit: www.bergenbio.com

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary

of Merck & Co., Inc. TARCEVA® is a registered trademark of OSI Pharmaceuticals,

LLC., marketed by Roche-Genentech.

-Ends-

Contacts

Richard Godfrey

CEO, BerGenBio ASA

+47 917 86 304

David Dible, Mark Swallow, Marine Perrier

Citigate Dewe Rogerson

bergenbio@citigatedr.co.uk

+44 207 638 9571

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.